Tibet Rhodiola Pharmaceutical Holding Co.

SHSE:600211 Stock Report

Market Cap: CN¥11.5b

Tibet Rhodiola Pharmaceutical Holding Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yuan Dong Guo

Chief executive officer

CN¥3.4m

Total compensation

CEO salary percentagen/a
CEO tenure7.8yrs
CEO ownershipn/a
Management average tenure7.8yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Is Using Debt Safely

Jan 02
These 4 Measures Indicate That Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Is Using Debt Safely

Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

Nov 27
Investors Holding Back On Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211)

At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Sep 25
At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Jul 29
Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Jul 12
Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

May 21
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

May 03
Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Mar 22
Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

CEO

Yuan Dong Guo (52 yo)

7.8yrs

Tenure

CN¥3,437,900

Compensation

Mr. Yuan Dong Guo serves as General Manager and Director of Tibet Rhodiola Pharmaceutical Holding Company since May 8, 2017. Mr. Guo served as the Chairman of the Board of Directors and Deputy General Mana...

Leadership Team

NamePositionTenureCompensationOwnership
Yuan Dong Guo
GM & Director7.8yrsCN¥3.44mno data
Jun Chen
Financial Director5.3yrsCN¥736.70kno data
Lan Liu
Deputy GM & Secretary of the Board7.8yrsCN¥1.07mno data

7.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 600211's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yuan Dong Guo
GM & Director7.8yrsCN¥3.44mno data
Dabin Chen
Chairman of the Board7.8yrsCN¥3.44mno data
Yu Cheng Zhou
Vice Chairman of the Board7.8yrsCN¥1.81mno data
Pei Yao
Chairman of the Supervisory Board7.8yrsno datano data
Sanyan Wu
Director4.8yrsCN¥80.00kno data
Ma Lie Yi
Director7.8yrsCN¥80.00kno data
Tiantian Tang
Supervisor5.8yrsno datano data
Yu Zhang
Independent Director3.2yrsCN¥180.00kno data

7.8yrs

Average Tenure

49.5yo

Average Age

Experienced Board: 600211's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 21:04
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tibet Rhodiola Pharmaceutical Holding Co. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weina JiangEverbright Securities Co. Ltd.
Wen Liang CuiFounder Securities Co., Ltd.
Zhouyu DengGuosen Securities Co., Ltd.